This is a working overview of RP-HPLC, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-09-05. Anything still debated is marked as such rather than presented as settled.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
==== Safety ==== The safety of red yeast rice (RYR) products has not been established. Some supplements have been found to contain high levels of citrinin, which can be toxic to the liver, kidneys, and cellular DNA. Commercial products also have highly variable amounts of monacolins and rarely declare this content on the label, making risk assessment difficult. Ingredient suppliers have been suspected of "spiking" red yeast rice preparations with purified lovastatin. One published analysis reported several commercial products as being almost entirely monacolin K—which would occur if the drug lovastatin was illegally added—rather than the expected composition of many monacolin compounds. There are reports in the literature of muscle myopathy and liver damage resulting from red yeast rice usage. From a review: "The potential safety signals of myopathies and liver injury raise the hypothesis that the safety profile of RYR is similar to that of statins. Continuous monitoring of dietary supplements should be promoted to finally characterize their risk profile, thus supporting regulatory bodies for appropriate actions." The European Food Safety Authority (EFSA) Panel on Food Additives and Nutrient Sources added to Food concluded that when red yeast rice preparations contained monacolins, the Panel was unable to identify an intake that it could consider as safe. The reason given was case study reports of severe adverse reactions to products containing monacolins at amounts as low as 3 mg/day. Red yeast rice is not recommended during pregnancy or breast-feeding.
== Current research == Since the Human Genome Project developed a blueprint of all human genes in our chromosomes, proteomics researchers have pushed to understand how that blueprint creates life. Diseases and infections are often the result of proteins going wrong, and finding the aberrant one requires sifting through thousands of other proteins. In addition, many problem proteins have not been given names yet or are too rare to find easily. In the last few years, Smith and his team have led work that has reduced analytical steps from hours to minutes. This increased speed has enabled many samples to be processed faster in high-throughput experiments. Smith has led other advances in sensitivity and accuracy that have improved the ability to find rare proteins, bringing proteomics technology to the doorstep of clinical researchers. Smith and collaborators have applied the technology to liver disease and cancer in the hopes of finding rare markers of disease in blood, making diagnosis or treatment safer and faster. In 2007, Scientific American magazine listed Smith and his collaborator Desmond Smith as one of the top 50 researchers for work to understand the origins of Parkinson's disease by mapping where proteins amass in diseased mouse brains. Among other work, Smith and colleagues at PNNL looked at how bacteria and viruses might cause illness. They've learned breast cancer leaves traces in the blood that doctors might research on someday. Smith led early studies for DOE into possible roles for microbes in making biofuels.
=== Aftermath === In April 1864, the East Tennessee Union Convention reconvened in Knoxville, and while its delegates were badly divided, several, including Brownlow and Maynard, supported a resolution recognizing the Emancipation Proclamation. Confederate businessman Joseph Mabry and future business leaders such as Charles McClung McGhee and Peter Kern began working with Union leaders to rebuild the city. Brownlow remained vengeful, however, seizing the property of Confederate leaders J.G.M. Ramsey, William Sneed (including the Lamar House Hotel), and William Swan, and expelling known Confederate sympathizers from the city. Acts of Civil War-related violence occurred in Knoxville for years after the war. On September 4, 1865, Confederate soldier Abner Baker was lynched in Knoxville after killing a Union soldier who had killed his father. On July 10, 1868, Union major E.C. Camp shot and killed Confederate colonel Henry Ashby on Main Street in front of the courthouse over a Civil War grievance. On June 13, 1870, Joseph Mabry shot pro-Union attorney John Baxter in front of the Lamar House, capping a feud that had been building since the war. The following year, David Nelson, the son of pro-Union congressman T.A.R. Nelson, shot and killed Confederate general James Holt Clanton on Gay Street in front of the Lamar House.
In the U.S., the Federal Food, Drug, and Cosmetic Act groups skin care products into two main categories: cosmetics and drugs. While prescription drugs must go through a strict approval process before they can be sold, cosmetics do not need FDA approval before being sold, although they are still monitored for labeling, safety, and are regulated. Cosmeceutical and nutricosmetic are marketing terms with no scientific evidence pertaining to skin care or health, and no acceptance for validity as skin care products under US law.
== External links == Clinical trial number NCT06470828 for "A Study of TAK-861 for the Treatment of Narcolepsy Type 1" at ClinicalTrials.gov Clinical trial number NCT06505031 for "A Study of TAK-861 in People With Narcolepsy Type 1" at ClinicalTrials.gov
Sources: en.wikipedia.org
== Key factors == There are many factors that contribute to a person's weight, including: diet, physical activity, genetics, environmental factors, health care support, medications, and illnesses. Each of these factors affects weight in different ways and to varying degrees, but health professionals most often stress the importance of diet and physical activity because they can be affected by conscious behavior modification. Attaining a healthy weight involves recognition of general techniques such as portion sizing, self-monitoring, and daily diet consistency. Once this healthy weight has been attained, maintaining this stable weight additionally involves physical activity and control of an individual's environment and eating patterns. Furthermore, healthcare support in the form of primary care medical supervision and following up over time has been shown to be helpful for long-term weight management. The following is a review of some of the key components of weight management in humans.
Often used to describe regions affected in diseases like multiple sclerosis. PET scan (Positron Emission Tomography) A neuroimaging technique that uses radioactive tracers to measure metabolic processes, often used to study brain activity, neurotransmitter systems, and disease progression. Phantom limb A phenomenon in which amputees feel sensations, including pain, in a limb that is no longer present. Thought to result from cortical reorganization. Phenotype The observable characteristics of an organism resulting from the interaction of its genotype with the environment. In neuroscience, may include behavioral traits, brain structure, or disease symptoms. Phineas Gage A famous historical case in neuroscience involving a railroad worker who survived a frontal lobe injury, providing early evidence of the brain’s role in personality and behavior. Photoreceptor A specialized neuron in the retina (rods and cones) that converts light into neural signals for visual processing. Pia mater The innermost of the three meninges surrounding the brain and spinal cord. It closely follows the contours of the brain surface. Place cell A neuron in the hippocampus that becomes active when an animal is in a specific location. Central to the brain’s internal spatial mapping system. Plasticity The brain's ability to adapt and reorganize itself through experience, learning, or following injury. See also neuroplasticity. Pons A structure in the brainstem that relays signals between the cerebrum and cerebellum, and plays roles in sleep, respiration, and facial sensation.
Such an organization requires the issuing of special laws by the governing state, since they are not covered by the normal administrative structure of the respective states. In 2010 only three Kommunalverbände besonderer Art exist.
=== Boiled === Eto is a Ghanaian traditional dish made from boiled and mashed yam or plantain and typically savored with boiled eggs, groundnut (peanuts) and sliced avocado. For the plantain option called 'Boodie eto', the plantain can be used unripe, slightly ripe or fully ripe. Culturally, eto was fed to a bride on the day of her marriage, but is now a popular dish enjoyed outside of special occasions as well. A traditional mangú from the Dominican Republic consists of peeled and boiled green plantains, mashed with hot water to reach a consistency slightly stiffer than mashed potatoes. It is traditionally eaten at breakfast, topped with sautéed red onions in apple cider vinegar and accompanied by fried eggs, fried cheese or fried bologna sausage, known as Dominican salami. Plantain porridge is also a common dish throughout the Caribbean, in which cooking bananas are boiled with milk, cinnamon, and nutmeg to form a thick porridge typically served at breakfast.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.